Compare Tango Therapeutics Inc. (TNGX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Xylem, Inc. — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Xylem, Inc. trades at $103.51 (market cap $23.99B). The key difference: Xylem, Inc. is far larger — about 6.4× Tango Therapeutics Inc.'s market cap, and Xylem, Inc. pays a 1.67% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Xylem, Inc. for 51 Days on average.
| TNGX | XYL | |
|---|---|---|
Market Cap | $3.74B | $23.99B |
Volume | 3,438,781 | 2,429,384 |
Sector | Health | Industrials |
52-Week High | $32.90 | $152.95 |
52-Week Low | $7.50 | $100.92 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $2.76B | $25.77B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Xylem (XYL) trades at $102.54, down slightly by 0.05% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results due October 27, 2026. Revenue has grown from $5.5B in 2022 to $9.04B in 2025, with net income margins improving to 10.59%. Recent developments include a $1.5B senior note offering to fund acquisitions of Cornell Pump and Roper Pump, alongside a new CFO appointment.
The outlook is supported by steady revenue growth, margin expansion, and strategic acquisitions in water technology, though near-term sentiment is cautious due to technical weakness and China-related headwinds. Risks include execution of acquisitions and debt increase, but analyst consensus price target of $146.63 implies significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
